Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aurora B

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Aurora B. Displaying page 1 of 1.
    EudraCT Number: 2011-006113-34 Sponsor Protocol Number: XAMNPIOAP2011 Start Date*: 2013-10-24
    Sponsor Name:AURORA PUJOL ONOFRE
    Full Title: Effect of pioglitazone administred to patients with Adrenomyeloneuropathy: A phase II, Singlearm, Monocentric Trial.
    Medical condition: X-linked adrenoleukodystrophy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000698-38 Sponsor Protocol Number: MD1003CT2014-01AMN Start Date*: 2014-08-13
    Sponsor Name:MEDDAY SAS
    Full Title: MD1003 IN ADRENOMYELONEUROPATHY: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY
    Medical condition: Adrenomyeloneuropathy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10069075 Adrenomyeloneuropathy without cerebral involvement LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-016773-15 Sponsor Protocol Number: HepVac Start Date*: 2010-01-13
    Sponsor Name:Matti Ristola
    Full Title: A Randomized, Controlled, Open-label Study of Comparing Immunogenicity of Sequential Hepatitis B and Hepatitis A Vaccination vs Vaccination with a Dual Hepatitis B and Hepatitis A Vaccine among HI...
    Medical condition: Immunisaatio A- ja B-hepatiittia vastaan HIV-infektoituneilla henkilöillä
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021430 Immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001042-18 Sponsor Protocol Number: J1O-MC-JZHD Start Date*: 2020-11-03
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma
    Medical condition: Relapsed/Refractory Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000609-32 Sponsor Protocol Number: C14011 Start Date*: 2012-09-06
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine
    Medical condition: Relapsed or Refractory Aggressive B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005542-23 Sponsor Protocol Number: CR0708-11 Start Date*: 2009-07-27
    Sponsor Name:Cancer Research UK
    Full Title: A CCLG/Cancer Research UK Phase I Trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and r...
    Medical condition: Relapsed and refractory solid tumours in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-023313-57 Sponsor Protocol Number: INF Start Date*: 2012-04-10
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Homing potential of the antigen specific B cell and antibody mediated immune response after vaccination
    Medical condition: Basic healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020729-42 Sponsor Protocol Number: LDOS002 Start Date*: Information not available in EudraCT
    Sponsor Name:Helix BioPharma Corp
    Full Title: A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients
    Medical condition: Inoperable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-006977-34 Sponsor Protocol Number: C14005 Start Date*: 2009-05-11
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
    Medical condition: Acute myelogenous leukemia (AML) and high-grade myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    11.1 10028533 LLT
    11.1 10000886 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-011428-79 Sponsor Protocol Number: C14008 Start Date*: 2012-10-09
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Perito...
    Medical condition: Adenocarcinoma of the breast (Phase 1 only). Ovarian Cancer, defined to include recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (Phases 1 and 2).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058448 Peritoneal adenocarcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006173 Breast adenocarcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000473-23 Sponsor Protocol Number: CULM20236 Start Date*: 2019-08-19
    Sponsor Name:OncoVerity Inc
    Full Title: A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006981-27 Sponsor Protocol Number: C14007 Start Date*: 2011-01-13
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or G...
    Medical condition: Phase I portion of the study - Advanced nonhematologic malignancies. Phase II portion of the study - Non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), adenocarcinoma of the esop...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006173 Breast adenocarcinoma LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 23:05:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA